Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Durvalumab + Tremelimumab in Pulmonary Sarcomatoid Carcinoma

NCT03022500 is registered in ClinicalTrials.gov with Seoul National University Hospital as lead sponsor.

NCT NCT03022500
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03022500 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Durvalumab + Tremelimumab in Pulmonary Sarcomatoid Carcinoma
Lead sponsor
Seoul National University Hospital
Phase
Phase 2
Overall status
Completed
Start date
May 18, 2017
Completion date
November 30, 2019
Enrollment
32 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

durvalumab + tremelimumab combination treatment, pulmonary sarcomatoid carcinoma, nsclc